Two late-stage studies of Merck's HIV therapy have met primary goals

On December 19th, Jinshi Data reported that Merck announced on Thursday that its experimental combination therapy for some adult HIV-1 patients has achieved the primary efficacy and safety goals in two late-stage studies. The company stated that its Doravirine/Islatravir combination therapy is not inferior to Gilead Sciences’ triple combination tablet Biktarvy and other various antiretroviral therapies in terms of viral replication inhibition. Merck plans to submit the data to regulatory authorities and present detailed research results at future medical conferences.

View Original
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
0/400
No comments
Trade Crypto Anywhere Anytime
qrCode
Scan to download Gate App
Community
English
  • 简体中文
  • English
  • Tiếng Việt
  • 繁體中文
  • Español
  • Русский
  • Français (Afrique)
  • Português (Portugal)
  • Bahasa Indonesia
  • 日本語
  • بالعربية
  • Українська
  • Português (Brasil)